Axsome Therapeutics Acquires Global Rights to Balipodect from Takeda

Shots:Axsome has entered into an asset purchase agreement with Takeda for TAK-063 (balipodect), with an intention to develop it for treating schizophrenia & Tourette syndrome (P-III trial-enabling activities for schizophrenia to begin in 2026)As per the deal, Axsome gains global rights to develop, manufacture, & commercialize TAK-063, while Takeda receives an upfront payment,…

ByRidhi RastogiApril 1, 2026

NEWS

GSK Reports the NMPA Approval of Exdensur (Depemokimab) for Severe Asthma

Shots:The Chinese NMPA has approved Exdensur as an add-on maintenance therapy for asthma pts (≥12yrs.) characterised by an eosinophilic phenotype based on P-III (SWIFT-1: n=382) & (SWIFT-2: n=380) trials Exdensur reduced asthma exacerbations by 58% (SWIFT-1) & 48% (SWIFT-2) over 52wks., with results in Chinese pts (n=58, SWIFT-1) consistent with the overall population. Pooled data…

ByRidhi RastogiApril 1, 2026

NEWS

Frontier Medicines Grants Ex-China Rights of FMC-220 to LG Chem

Shots:Frontier has granted LG Chem an exclusive global license to develop & commercialize FMC-220 outside of Greater China, with Frontier retaining full rights in Greater ChinaAs per the deal, LG will handle regulatory filings, global clinical development, & commercialization in licensed regions, while Frontier may partially fund confirmatory trials & receive upfront, clinical,…

ByRidhi RastogiApril 1, 2026

NEWS

Biogen to Acquire Apellis Pharmaceuticals for ~$5.6B

Shots:Biogen to acquire Apellis, incl. its assets Empaveli, Syfovre & felzartamab, for $41/share plus a non-transferable CVR, representing an upfront equity consideration of ~$5.6B, with remaining shares acquired later via a second-step mergerCVR holders will receive $2/CVR if Syfovre achieves $1.5B sales (2027-2030), an additional $2 if it reaches $2B in the same…

ByRidhi RastogiApril 1, 2026

NEWS

Elidah Reports US FDA Clearance of Elitone for Men to Treat Post-Prostatectomy Urinary Incontinence

Shots:The US FDA has granted clearance to Elitone for Men to help restore bladder control after prostate surgery, with US availability expected in Apr 2026Elitone for Men is a non-invasive, at-home therapy that delivers neuromuscular stimulation to strengthen pelvic floor muscles, improving bladder control, with a simple 20min. daily use enabling consistent treatment…

ByRidhi RastogiApril 1, 2026

NEWS

Merck Signs ~$838M AI-Driven Antibody Discovery Deal with Infinimmune

Shots:Infinimmune has partnered with Merck to discover & develop antibody candidates against multiple undisclosed targets selected by Merck using Infinimmune’s human-first antibody discovery platformAs per the deal, Infinimmune will use its Anthrobody discovery platform & Glimpse antibody language model to discover & optimize antibodies from human immune repertoires, enabling large-scale B-cell screening to…

ByRidhi RastogiApril 1, 2026

NEWS

Eli Lilly to Acquire Centessa Pharmaceuticals in a Deal Valued at ~$7.8B

Shots:Eli Lilly has entered into a definitive agreement to acquire Centessa Pharmaceuticals incl. its asset cleminorexton & ORX142, expanding Lilly's neuroscience portfolio & capabilities into sleep medicineAs per the deal, Lilly will acquire all issued & to-be-issued share capital of Centessa (incl. ADSs) for $38/share in cash (~$6.3B upfront), plus a non-transferable CVR of…

ByRidhi RastogiMarch 31, 2026

NEWS

Blackstone Closes $6.3B BXLS VI Fund, Making it the Largest Life Sciences Vehicle

Shots:Blackstone has closed Blackstone Life Sciences VI (BXLS VI) at its hard cap of $6.3B of total capital commitments, making it ~40% larger than its predecessor vehicleBlackstone launched BXLS platform in 2018, with ~$15B in assets under management as of Q4’25 & invests across the lifecycle of drugs and medtech, with an ~86%…

ByRidhi RastogiMarch 31, 2026

NEWS

CVC Capital Partners Proposes ~€10.9B Acquisition of Recordati

Shots:Recordati has received a non-binding indication of interest from CVC Capital Partners for a voluntary tender offer to acquire all outstanding shares & delist the company, subject to due diligence, financing, & partner identificationRecordati expanded into rare diseases with its 2021 acquisition of EUSA Pharma for ~$845M, strengthening its rare cancer portfolioThe…

ByRidhi RastogiMarch 31, 2026

NEWS

Merck Reports P-III (CORALreef AddOn) Trial Data on Enlicitide Decanoate in Hypercholesterolemia

Shots:Trial assessed enlicitide (QD, PO) vs non-statin therapies (PO) added to background statins in adults with hypercholesterolemia & ASCVD risk or history, meeting its 1EP with a 64.6% LDL-C reduction at 8wks. & reductions of 56.7% vs bempedoic acid, 36% vs ezetimibe, & 28.1% vs their combinationTrial also showed 8wk. reductions in ApoB…

ByRidhi RastogiMarch 31, 2026

Ridhi Rastogi

Axsome Therapeutics Acquires Global Rights to Balipodect from Takeda

GSK Reports the NMPA Approval of Exdensur (Depemokimab) for Severe Asthma

Frontier Medicines Grants Ex-China Rights of FMC-220 to LG Chem

Biogen to Acquire Apellis Pharmaceuticals for ~$5.6B

Elidah Reports US FDA Clearance of Elitone for Men to Treat Post-Prostatectomy Urinary Incontinence

Merck Signs ~$838M AI-Driven Antibody Discovery Deal with Infinimmune

Eli Lilly to Acquire Centessa Pharmaceuticals in a Deal Valued at ~$7.8B

Blackstone Closes $6.3B BXLS VI Fund, Making it the Largest Life Sciences Vehicle

CVC Capital Partners Proposes ~€10.9B Acquisition of Recordati

Merck Reports P-III (CORALreef AddOn) Trial Data on Enlicitide Decanoate in Hypercholesterolemia

Contact US

FOLLOW US